產品詳情
簡單介紹：
Anti-Membralin抗體產品質量穩定，實驗效果明顯，貨期快，價格優惠，歡迎垂詢訂購！我公司長期供應**組化抗體、WB抗體、**組化試劑盒和抗體試驗所需全部相關試劑、熒光標記抗體、單克隆抗體、多克隆抗體、各種標記的二抗IgG/IgM/IgD/IgA等科研實驗抗體。Anti-Membralin抗體用于**組化實驗,WB實驗,相應的標記抗體有HRP標記抗體,FITC標記,BIO等。
詳情介紹：
Rabbit Anti-Membralin
Cat. Number:
Anti-Membralin抗體KL-11322R
Quantity size:
0.2ml
Concentration:
1mg/ml Buffer = 0.01M TBS(pH7.4) with 1% BSA, 0.03% Proclin300 and 50% Glycerol.
Background:
The gene encoding human Membralin, C19orf6, localizes to chromosome 19p13.3. It contains 11 exons, which encode at least two splice variants in human cancer. Membralin is a multi-pass membrane protein and exists either as a long or short form. The long form of Membralin comprises all 11 exons, while the shortAnti-Membralin抗體 form contains all exons except exon 10. Expression of different Membralin isoforms depends on tissue type. The long form is expressed in ovarian and colorectal carcinomas, whereas the short form is expressed in breast or pancreatic carcinomas. Because Membralin expression in ovarian carcinomas is highest in serous carcinomas as compared to surface epithelium carcinomas, expression of Membralin may be useful as a novel tumor-associated marker in ovarian serous carcinomas.
Also known as:
ASBABP1; C19orf6; MGC4022; Anti-Membralin抗體R32184_3; aspecific BCL2 ARE-binding protein 1; C19orf6; chromosome 19 open reading frame 6; MBRL; MBRL_HUMAN.
Specificity:
●
Rabbit Polyclonal IgG, affinity purified by Protein A.
●
Reacts with: Human, Mouse, Rat,Anti-Membralin抗體 Dog, Pig, Cow, Sheep, Zebrafish.
●
Immunogen: KLH conjugated synthetic peptide derived from human Membralin.
●
Predicted Molecular Weight: 68kDa.
Storage:
Shipped at 4℃, Store at -20℃ (Avoid repeated freeze/thaw cycles).
Application:
WB=1:100-500 ELISA=1:500-1000 IHC-P=1:100-500 IHC-F=1:100-500 ICC=1:100-500 IF=1:100-500
Not yet tested in other applications. Anti-Membralin抗體
Optimal working dilutions must be determined by the end user.
Not yet tested in other applications. Anti-Membralin抗體
Optimal working dilutions must be determined by the end user.
